Teva Pharmaceutical Industries Limited is a global pharmaceutical company headquartered in Petach Tikva, Israel, specializing in the development, production, and marketing of generic and specialty medicines, as well as active pharmaceutical ingredients. Founded in 1901, Teva is recognized as one of the largest generic drug manufacturers worldwide, with a significant market presence in North America, Europe, Japan, Russia, and Israel. The company offers a diverse range of products, including sterile medicines, hormones, and cytotoxic drugs in various forms such as tablets, injectables, and creams. Teva's specialty medicines target therapeutic areas including central nervous system disorders, with notable products like Copaxone, AJOVY, and AUSTEDO, as well as respiratory treatments such as ProAir and QVAR. In oncology, Teva markets medications like Bendeka and Treanda. The company also engages in collaborations with other pharmaceutical firms and maintains a robust supply chain to support its extensive portfolio.
Heptares Therapeutics Ltd. is a clinical-stage drug discovery company based in Welwyn Garden City, United Kingdom, founded in 2007. The company specializes in developing novel small-molecule medicines that target G protein-coupled receptors (GPCRs), a significant family of druggable targets associated with various human diseases. Heptares has pioneered a proprietary technology for producing purified, stabilized, and functional GPCRs, known as Stabilised Receptors (StaRs), which addresses a key challenge in drug development. Its research focuses on treatments for conditions such as Alzheimer's disease, ADHD, diabetes, schizophrenia, and migraines. Heptares maintains strategic collaborations with several organizations, including Pfizer and Kymab, to enhance its drug discovery efforts. As of 2015, Heptares operates as a subsidiary of Sosei Group Corporation.
Anda, Inc. is a wholesale distributor of pharmaceutical products in the United States, supplying a wide range of items including generic, branded, and specialty pharmaceuticals, as well as controlled substances, vaccines, injectables, medical and surgical supplies, and over-the-counter products. The company caters to independent pharmacies, pharmacy chains, hospitals, nursing homes, mail order pharmacies, and physicians' offices, facilitating orders through phone, fax, and online platforms. Founded in 1992 and based in Weston, Florida, Anda, Inc. was previously known as Anda Generics, Inc. and adopted its current name in October 1999. It operates as a subsidiary of Watson Pharmaceuticals, Inc.
WaVe Life Sciences Ltd. is a clinical stage genetic medicine company focused on developing novel stereopure oligonucleotides through its proprietary PRISM platform. The company aims to address genetic defects by either reducing the expression of harmful proteins or converting dysfunctional mutant proteins into functional ones. It primarily concentrates on neurological disorders affecting the central and neuromuscular systems. WaVe Life Sciences has established research and collaboration agreements with major pharmaceutical companies to advance its oligonucleotide therapeutics. Founded in 2012, the company is headquartered in Singapore and maintains research facilities in Boston and Japan. The organization was established by leading scientists in the field of chemistry and life sciences, underscoring its commitment to innovative approaches in nucleic acid therapeutics.
Representaciones e Investigaciones Médicas (Rimsa)
Acquisition in 2015
Rimsa, a leading pharmaceutical manufacturing and distribution company in Mexico
CareTRx by Gecko Health is a product and services to improve poor medication adherence for asthma and COPD medication. The company offers a unique solution based on direct monitoring, games and social tools that motivate patients, engage care-givers, and inform clinicians. GeckoCap simplifies adherence to help families and lower costs.
Actavis plc (NYSE: ACT) is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. The Company has global headquarters in Dublin, Ireland and Administrative Headquarters in Parsippany, New Jersey, USA. http://www.allergan.com/products/key-products/generic-products
MicroCHIPS Biotech, Inc. specializes in developing a microchip-based implant designed for drug delivery applications across various therapeutic areas, including osteoporosis, diabetes, multiple sclerosis, women’s contraception, and pain management. This innovative implant can store and release precise doses of medication over extended periods, offering an alternative to traditional therapies that rely on frequent injections. The implant is surgically placed under the skin during a minimally invasive procedure and can be wirelessly activated or deactivated by healthcare providers or patients. Additionally, the device allows for real-time adjustments to the drug dosage and frequency, catering to the specific needs of each patient. Established in 1999 and headquartered in Lexington, Massachusetts, MicroCHIPS operates as a subsidiary of Daré Bioscience, Inc.
Auspex Pharmaceuticals is a biopharmaceutical company dedicated to developing and commercializing innovative medicines for orphan diseases. Its pipeline features product candidates aimed at addressing unmet medical needs in conditions such as hyperkinetic movement disorders, which include chorea associated with Huntington’s disease, tardive dyskinesia, and Tourette syndrome. Additionally, the company is involved in creating deuterated analogs of clinically validated drugs, enhancing existing therapies across various therapeutic areas, including respiratory diseases and inflammation. Through its focused approach, Auspex Pharmaceuticals seeks to improve treatment options for patients with specific medical conditions.
Ignyta is a scientifically-driven biotechnology company catalyzing personalized medicine in autoimmune diseases. Their goal is to revolutionize the quality of biomarkers and tests available to rheumatologists and patients to help them make better informed, more individualized treatment decisions; and to identify truly novel autoimmune disease targets for biopharmaceutical companies to enable the development of precise therapies for patients worldwide.
Ignyta was incorporated in 2011 and operates in San Diego, California.
Labrys Biologics
Acquisition in 2014
Labrys Biologics Inc., a company focused on treatments for chronic migraine. Labrys Biologics has acquired worldwide rights to RN-307 from Pfizer Inc. RN-307 is an antibody for the treatment of chronic migraine.
NuPathe Inc. is a specialty pharmaceutical company dedicated to developing and commercializing innovative therapies for neurological and psychiatric disorders. The company's flagship product is Zecuity, a transdermal system utilizing sumatriptan for the acute treatment of migraines in adults. In addition to Zecuity, NuPathe is advancing a pipeline of product candidates, including NP201, designed for the continuous treatment of Parkinson's disease, and NP202, aimed at the long-term management of schizophrenia and bipolar disorder. Both candidates leverage the company's proprietary Long-Acting Delivery technology, which facilitates extended medication release through biodegradable implants. Founded in 2005 and based in Malvern, Pennsylvania, NuPathe operates as a subsidiary of Teva Pharmaceutical Industries Limited. The company actively seeks partnerships to enhance the commercial potential of its products in the United States and internationally.
MicroDose Therapeutx is a specialty pharmaceutical company developing next-generation drug delivery products. Most notable are the novel electro-mechanical dry powder inhaler and PolyCap technologies.
Gamida Cell Ltd. is a clinical-stage biopharmaceutical company focused on developing innovative cell therapies for blood cancers and serious blood diseases. The company's lead product candidate, omidubicel, utilizes expanded hematopoietic stem cells and differentiated immune cells, and is currently undergoing Phase 3 trials for high-risk hematologic malignancies, alongside Phase 1/2 trials for severe aplastic anemia. Additionally, Gamida Cell is advancing GDA-201, a natural killer cell-based immunotherapy, which is in Phase 1/2 studies for relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. Founded in 1998 and headquartered in Jerusalem, Israel, the company leverages a proprietary expansion platform that enhances the therapeutic potential of umbilical cord blood-derived cells and natural killer cells, aiming to address significant unmet clinical needs in the field of regenerative medicine.
Cocrystal Discovery is a privately funded biotechnology company developing antiviral therapeutics for human diseases. Cocrystal has breakthrough technologies that enable the creation of first- and best-in-class antivirals. Their mission today is to discover and develop small molecule inhibitors of the viral replication complex.
Cephalon is a global biopharmaceutical company dedicated to discovering, developing and bringing to market medications to improve the quality of life of individuals around the world. Since its inception in 1987, Cephalon has brought first-in-class and best-in-class medicines to patients in several therapeutic areas. Cephalon has the distinction of being one of the world's fastest-growing biopharmaceutical companies, now among the Fortune 1000 and a member of the S&P 500 Index, employing approximately 4,000 people worldwide. The company sells numerous branded and generic products around the world. In total, Cephalon sells more than 150 products in nearly 100 countries.
Gamida Cell Ltd. is a clinical-stage biopharmaceutical company focused on developing innovative cell therapies for blood cancers and serious blood diseases. The company's lead product candidate, omidubicel, utilizes expanded hematopoietic stem cells and differentiated immune cells, and is currently undergoing Phase 3 trials for high-risk hematologic malignancies, alongside Phase 1/2 trials for severe aplastic anemia. Additionally, Gamida Cell is advancing GDA-201, a natural killer cell-based immunotherapy, which is in Phase 1/2 studies for relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. Founded in 1998 and headquartered in Jerusalem, Israel, the company leverages a proprietary expansion platform that enhances the therapeutic potential of umbilical cord blood-derived cells and natural killer cells, aiming to address significant unmet clinical needs in the field of regenerative medicine.
TransPharma Medical Ltd. is a specialty pharmaceutical company dedicated to the development and commercialization of innovative drug products using advanced transdermal drug delivery technology. The company focuses on creating solutions that enable painless delivery of peptide and protein therapeutics. Its flagship product, ViaDerm-hPTH (1-34), is designed to treat osteoporosis and is currently undergoing Phase 2B clinical trials in collaboration with Eli Lilly. In addition to this, TransPharma Medical is advancing two other peptide products that are in Phase 1 of clinical development. Through its proprietary delivery systems, the company aims to improve patient outcomes in the treatment of various conditions.
BioLineRx Ltd. is a clinical-stage biopharmaceutical development company based in Modi’in, Israel, specializing in oncology. The company’s development pipeline includes several therapeutic candidates, such as BL-8040, a peptide aimed at treating solid tumors and hematological malignancies, as well as facilitating stem cell mobilization. Another candidate, AGI-134, is an immuno-oncology agent designed for solid tumors, while BL-5010 is a proprietary applicator intended for the non-surgical removal of skin lesions. BioLineRx has established collaborations with notable organizations, including a partnership with MSD in the cancer immunotherapy field, and agreements with MD Anderson Cancer Center and Genentech Inc. to explore combinations of BL-8040 with existing therapies in clinical studies for pancreatic and other solid tumors. Founded in 2003, BioLineRx is dedicated to addressing unmet medical needs and improving treatment options in oncology.
Proneuron Biotechnologies focuses on developing innovative therapies aimed at treating spinal cord injuries and other central nervous system disorders. The company employs proprietary technology that modulates the interaction between the nervous and immune systems, which enhances cell therapy options for spinal cord-related injuries. In addition to spinal cord injury treatments, Proneuron is actively researching potential cures for paralysis and various neurological conditions, positioning itself as a key player in advancing therapeutic solutions in this critical area of healthcare.
Copley Pharmaceutical
Acquisition in 1999
Copley Pharmaceutical is a generic pharmaceutical company that manufactured products for both over-the-counter and prescription sales.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.